Differential use of FasL-and perforin-mediated cytolytic mechanisms by T-cell subsets involved in graft-versus-myeloid leukemia responses

Blood

Volumn 96, Issue 3, 2000, Pages 1047-1055

  Hsieh, Michael H ^a   Korngold, Robert ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; FAS LIGAND; PERFORIN; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; GRAFT VERSUS LEUKEMIA EFFECT; LEUKEMIA CELL LINE; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; MYELOID LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION;

EID: 0034254473     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.3.1047.015k36_1047_1055     Document Type: Article

References (63)

1. Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia
2. Graft-versus-myeloma effect: Proof of principle
3. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer
4. Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. A prospective, randomized, double-blind trial
5. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion
6. Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft- versus-host disease but may increase the risk of leukaemic relapse
7. Specific recognition of human leukemic cells by allogeneic T cells, II: Evidence for HLA-D restricted determinants on leukemic cells that are crossreactive with determinants present on unrelated nonleukemic cells
8. Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia
9. Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia
10. In vitro separation of host specific graft-versus-host and graft- versus-leukemia cytotoxic T cell activities
11. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation
12. Anti-leukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts
13. Graft-versus-leukemia reactions after bone marrow transplantation
14. Transplantation of patients with high risk acute myeloid leukemia in first remission with autologous marrow cultured in interleukin-2 followed by interleukin-2 administration
15. Induction of graft versus leukemia effect in bone marrow transplantation: Dosage and time schedule dependency of inter-leukin 2 therapy
16. Graft versus leukemia effect after transplantation with interleukin-2- activated bone marrow: Correlation with eradication of residual disease
17. Autologous GVHD following PBSCT, with evidence for a graft-versus- myeloma effect
18. Induction of graft versus leukemia effects by cell-mediated lymphokine-activated immunotherapy after syngeneic bone marrow transplantation in murine B cell leukemia
19. Cytokine-mediated immuno- therapy following autologous bone marrow transplantation in lymphoma and evidence of interleukin-2-induced immunomodulation in allogeneic transplants [see comments]
20. Allore-active CD4+ T lymphocytes can exert cytotoxicity to chronic myeloid leukaemia cells processing and presenting exogenous antigen
21. Graft-vs.-lymphoma effect in an allogeneic hematopoietic stem cell transplantation model
22. Granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation maintains GVL effects through a perforin-dependent pathway while preventing graft-versus-host disease
23. Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation
24. CD8+ T cells of Tc2 phenotype mediate a GVL effect and prevent marrow rejection
25. Graft-versus-myeloid leukemia responses following syngeneic and allogeneic bone marrow transplantation
26. A mouse c-myc retrovirus transforms established fibroblast lines in vitro and induces monocyte-macrophage tumors in vivo
27. The JAM test. A simple assay for DNA fragmentation and cell death
28. An endogenous 55 kDa TNF receptor mediates cell death in a neural cell line
29. Expression of an exogenous tumor necrosis factor (TNF) gene in TNF- sensitive cell lines confers resistance to TNF-mediated cell lysis
30. Reactivity of in-vitro-expanded alloimmune cytotoxic T lymphocytes and Qa-1 -specific cytotoxic T lymphocytes against AKR leukemia in vivo
31. Graft versus leukemia, 3: Apparent independent antihost and antileukemia activity of transplanted immunocompetent cells
32. Adoptive immunotherapy in conjunction with bone marrow transplantation: Amplification of natural host defense mechanisms against cancer by recombinant IL-2
33. Graft-versus-leukemia activity after bone marrow transplantation does not require graft-versus-host disease
34. Peripheral tolerance to host minor histocom-patibility antigens in radiation bone marrow chimeras abrogates lethal GVHD while preserving GVL effect
35. Interleukin-2 inhibits graft-versus-host disease-promoting activity of CD4+ cells while preserving CD4- and CD8-mediated graft-versus-leukemia effects
36. Recognition of peptides corresponding to the joining region of p210BCR-ABL protein by human T cells
37. Two brc-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes
38. BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors
39. Targeted T-cell therapy for human leukemia: Cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells
40. Association of natural killer cell immune recovery with a graft- versus-leukemia effect independent of graft-versus-host disease following allogeneic bone marrow transplantation
41. Graft-versus-leukemia activity can be predicted by natural cytotoxicity against leukaemia cells
42. Perforin-dependent cytotoxic activity and lymphokine secretion by CD4+ T cells are regulated by CD8+ T cells
43. A major role for the Fas pathway in acute graft-versus-host disease
44. The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice
45. Dissociation of severe lupus-like disease from polyclonal B cell activation and IL2 deficiency in C3H-lpr/lpr mice
46. Lpr and gld: Single gene models of systemic autoimmunity and lymphoproliferative disease
47. Perforin-deficient CD8+ T cells: In vivo priming and antigen-specific immunity against Listeria monocytogenes
48. CD4+ and CD8+ T cells each can utilize a perforin-dependent pathway to mediate lethal graft-versus-host disease in major histocompaiibility complex- disparate recipients
49. Identification of a population of CD4+ CTL that utilizes a perforin rather than a Fas ligand-dependent cytotoxic mechanism
50. Mechanisms of lysis by cytotoxic T lymphocyte clones: Lytic activity and gene expression in cloned antigen-specific CD4+ and CD8+ T lymphocytes
51. Establishment and functional characterization of human herpesvirus 6: Specific CD4+ human T-cell clones
52. Studies of the mechanism of cytolysis by HIV-1-specific CD4+ human CTL clones induced by candidate AIDS vaccines
53. Decreased tumor surveillance in perforin-deficient mice
54. Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies
55. Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation
56. The role of granzyme B in murine models of acute graft-versus-host disease and graft rejection
57. The role of tumor necrosis factor and interferon gamma in graft- versus-host disease and related immunodeficiency
58. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs-host disease
59. Role of mast cells in early epithelial target cell injury in experimental acute graft-versus-host disease
60. Selective activation of Fas/Fas ligand-mediated cytotoxicity by a self peptide
61. Distinct T cell receptor signaling requirements for perforin- or FasL- mediated cytotoxicity
62. Effects of epitope modification on T cell receptor-ligand binding and antigen recognition by seven H-2Kd-restricted cytotoxic T lymphocyte clones specific for a photoreactive peptide derivative
63. Altered peptide ligands trigger perforin rather than Fas-dependent cell lysis